Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Advaxis Announces Completion of Patient Accrual in Lovaxin C Phase I/II Trial
May 16th, 2007
Advaxis, Inc. (OTCBB: ADXS), a biotechnology company developing novel Listeria-based therapeutic cancer vaccines, has completed patient recruitment for the Phase I/II trial of Lovaxin C, a Listeria-based immunotherapy for cervical cancer, after dosing 15 patients in an escalating dose clinical trial that was conducted in Mexico, Serbia and Israel. The objective of this trial was to establish a range of safe doses up to a maximally tolerated dose, which has been achieved. The Company plans to complete patient reporting in July, report the results over the following 2 months, and submit an IND for Lovaxin C to the FDA by October, 2007. If the IND is approved, it would be...
Source: Vaccine Weekly (2007-05-16)
|
